Comparative Pharmacology
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE versus DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE versus DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5.
DOBUTAMINE HYDROCHLORIDE vs DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dobutamine directly stimulates β1-adrenergic receptors in the heart, increasing myocardial contractility and stroke volume with minimal chronotropic effect at therapeutic doses. It also has mild β2 and α1 activity.
Dobutamine is a direct-acting inotropic agent primarily stimulating β1-adrenergic receptors, with mild β2 and α1 activity, increasing cardiac contractility and stroke volume.
Intravenous infusion: 2.5-20 mcg/kg/min, titrated to hemodynamic response. Typical starting dose 2.5-5 mcg/kg/min.
IV continuous infusion: 2.5-20 mcg/kg/min titrated to hemodynamic response; start at 2.5-5 mcg/kg/min. Max dose: 40 mcg/kg/min.
None Documented
None Documented
2-3 minutes (short distribution half-life). Terminal elimination half-life is approximately 2 minutes. Clinical context: Requires continuous intravenous infusion for sustained effect due to rapid clearance.
Terminal elimination half-life is approximately 2 minutes. Short half-life necessitates continuous intravenous infusion for sustained hemodynamic effect.
Primarily renal (90-95% as inactive metabolites, mainly glucuronide conjugates and 3-O-methyl metabolites). Less than 5% excreted unchanged. Biliary/fecal elimination is minimal (<5% in feces).
Primarily renal (urinary) elimination; majority as metabolites (3-O-methyldobutamine and conjugates). Less than 5% excreted unchanged in urine. Minor biliary/fecal excretion.
Category C
Category C
Inotropic Agent
Inotropic Agent